#Nonalcoholic Steatohepatitis Treatment Market

[bommagoni]

Nonalcoholic Steatohepatitis Treatment Market Share [2030]

[martynnx-blog]

Nonalcoholic Steatohepatitis Treatment Market Growth Analysis by Manufacturers, Regions, Type and Application, Forecast Analysis to 2026

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Get Request Sample Copy @  https://www.coherentmarketinsights.com/insight/request-sample/2279

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/nonalcoholic-steatohepatitis-treatment-market-2279

[myabhijitr]

Nonalcoholic Steatohepatitis Treatment Market – Global Industry Outlook, and  Analysis, 2018-2026

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Get Free Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2279

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).

Rising incidence of nonalcoholic steatohepatitis and strong product pipeline are expected to drive the nonalcoholic steatohepatitis treatment market revenue

Nonalcoholic steatohepatitis has become one of the most common liver-related health problems. The condition has been linked to an unhealthy diet and weight gain, but it can also be observed in non-obese individuals. Increasing prevalence of insulin resistance, and obesity is expected to fuel the nonalcoholic steatohepatitis treatment market during the forecast period.

According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. According to the National Health and Nutrition Examination Survey (NHANES) 2014 data, in U.S. the percentage of obesity is higher in women, i.e. 40%, than in men, 35%.

Most therapies for NASH are in early- or mid-stage development and some are in late-stage studies. Multiple companies are focused on the development of drugs. In April 2018, AstraZeneca has licensed IONIS-AZ6-2.5-L, which has been renamed to AZD2693. The newly licensed drug is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis. In 2016 Bristol-Myers Squibb acquired rights for a NASH program from Osaka, Japan-based Nitto Denko Corporation.

Despite the significant burden to the public health system, there are no FDA-approved specifically tailored drugs for nonalcoholic steatohepatitis treatment. Therefore, there is an immense need for effective treatment to manage the complex pathophysiologic processes of NASH. Numerous medications targeting different stages and molecular events in the disease process are currently in the pipeline, increasing the promise of successful treatment of NASH in the future.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2279

Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[jesse-pinkman123]

The Nonalcoholic Steatohepatitis Treatment Market report presents a detailed competitive terrain of the global request. The request dynamics, drivers, and segmentation by operation, type, region, and manufacturer are all mooted in this report.

[expertofmarketinsights-blog]

Nonalcoholic Steatohepatitis Treatment Market Growth Factors 2018 – 2026

Nonalcoholic Steatohepatitis Treatment Market Growth Factors 2018 – 2026

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and…

[traderspro]

2 Beaten-Down Pharma Stocks Set For Explosive Growth In 2019

Many biotech stocks were riding high this summer, but have plunged in the last few months along with much of the rest of the market.

But for two drugmakers, this selloff looks overblown. And both could prove to be big winners next year with potential blockbuster drugs hitting the market.

Here’s what you need to know about these two stocks.

Viking Therapeutics (NASDAQ:VKTX)

What sets Viking Therapeutics (NASDAQ: VKTX) apart from most biotechs is that the drugmaker has not one, but two potential blockbuster treatments nearing late-stage development.

The first is a hip fracture drug candidate—VK5211—which Viking is seeking a partner for to assist financially with the drug’s expensive late-stage development. Viking is doing this to focus on its other promising candidate, VK2809, a treatment for the fatal liver condition known as nonalcoholic steatohepatitis (NASH).

NASH is expected to be worth upwards of $35 billion annually within the next two years, and there are currently no approved treatments for the disease so those companies that bring a product to market stand to rake in billions.

VKTX stock is down nearly 70% since peaking in September over concerns that the biotech’s NASH treatment is well behind in terms of development compared to its competitors in the space. However, Viking’s VK2809 candidate has demonstrated an arguably superior clinical profile compared to all other experimental competitor treatments of fatty liver disease, and there’s strong promise that these results will extend to the NASH arena.

Considering this, Viking’s sharp pullback may well prove to be unjustified and presents a great buying opportunity for investors interested in jumping into the multibillion-dollar profit opportunity that is NASH.

All analysts covering the stock rate it a Buy and their average twelve-month price target for VKTX is $26.29, indicating possible upside of 260%. Last month, Raymond James upgraded the stock to a Strong Buy and set their price target at $43 – 489% higher than Thursday’s closing price.

Amarin (NASDAQ:AMRN)

Amarin (NASDAQ: AMRN) sparked a flurry of headlines in late September after the company revealed unprecedented results for its prescription omega-3 fish oil pill, Vascepa, in a large cardiovascular trial.

Vascepa showed a 25% relative risk reduction in terms of major adverse cardiovascular events like heart attacks or strokes when taken in addition to a statin in patients with persistently elevated triglyceride levels. No other omega 3 supplement has demonstrated such incredible benefits within a large, placebo-controlled study.

The treatment isn’t likely to start seeing major sales until late in 2019. However, Amarin is planning to begin rolling out educational materials on Vascepa’s clinical results to doctors before a regulatory application is filed, which means the company could start to see sales from off-label prescriptions within the next few quarters.

The company’s management is expecting Vascepa’s sales to eventually top $2 billion per year, which is a huge number considering the drug is currently on-track to generate only about $221 million for all of 2018.

Another big draw for Amarin is that the company’s impressive results with the Vascepa study make the company an attractive takeover target for bigger pharma companies. Amarin shares could see a boost next year from a bidding war for the company, or from organic growth from sales of Vascepa. Either would mean a very interesting year ahead for this stock.

Analysts’ average price target for AMRN is $34.80, suggesting possible upside of 156% over the next twelve months. Last month, HC Wainwright adjusted their price target for the stock up to $51 – 275% above today’s closing price.

[healthcare-market]

Nonalcoholic Steatohepatitis Therapeutics Market : Value Chain, Stakeholder Analysis and Trends

Transparency Market Research (TMR) in its latest research report on the global nonalcoholic steatohepatitis therapeutics market has observed that players within this market both new entrants as well as those established are making equal efforts to develop an enhanced and effective treatment for NASH disease. Key players operating in the market include: Gilead Sciences, Inc., Zydus Cadila, GENFIT SA, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc., Astazeneca Plc., Immuron Ltd., Galmed Pharmaceuticals Ltd., and Tobira Therapeutics, Inc. Most of the leading biopharmaceutical companies are striving to develop novel therapeutics for NASH treatment and are carrying out clinical trials. Many of the companies are based in the U.S. and are collaborating with academic institutes and research centres so as to conduct clinical trials.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7691

According to Transparency Market Research (TMR), the global nonalcoholic steatohepatitis therapeutics market will cross US$20.27 bn by 2025. By drug type, the demand for elafibranor is highest on account of its effectiveness in reducing the effects of the NASH disease as well as the fact that it is the most advanced drug available as of now. The second most popular drug type is obeticholic acid (OCA).

Request for Analysis of COVID19 Impact on Nonalcoholic Steatohepatitis Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=7691

North America and Europe Remain Most Attractive Regional Markets for NASH Therapeutics

By geography, the nonalcoholic steatohepatitis therapeutics market is highly attractive in regions such as North America and Europe, as these two regions are majorly affected by NASH. The growth of this market is also associated with an increasing number of people in the region suffering from obesity and diabetes. The increasing incidences of high cholesterol as well as change in lifestyle are some of the other reasons behind the continued growth of the nonalcoholic steatohepatitis therapeutics market in these regions. High growth areas for nonalcoholic steatohepatitis therapeutics market in Europe include Germany, the U.K., Spain, Italy, and France.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=7691

Appalling Cases of Obesity among a Vast Pool of Population Worldwide Continues to Fuel Demand for Effective NASH Therapeutics

The growing incidences of NASH and nonalcoholic fatty liver diseases (NAFLD) among people worldwide is behind the rise in the demand for nonalcoholic steatohepatitis therapeutics. This demand is particularly high in the developed nations of North America and Europe. Research centres are putting in much efforts for finding an effective treatment for nonalcoholic steatohepatitis disease. The growing prevalence of obesity worldwide, including obese children have created a heightened concern and need for curing the NASH disease at an early stage and keep a check on the weight. Levels of cholesterol is also high among a vast pool of population today, especially in America and this will continue to fuel the growth of the nonalcoholic steatohepatitis therapeutics market. While no exact cure exists in the market today, the treatment for NAFLD and NASH is constantly being worked upon.

Buy now Nonalcoholic Steatohepatitis Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=7691&ltype=S

As of now, there are no therapies which have been approved and thus, there is high dependency on off label agents which offer sub-optimal efficacy and safety. There are many drugs in the later stages of the pipeline and this is expected to drive the growth prospects of the market.

The data and information presented in this review are based on a TMR report titled as “Nonalcoholic Steatohepatitis Therapeutics Market (Obeticholic Acid, Aramchol, Saroglitazar, and Elafibranor) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2025.”

More Trending Reports by Transparency Market Research:

https://www.prnewswire.com/news-releases/topical-oral-medications-core-of-acne-scar-treatment-market-growth-trajectory--tmrs-study-301341979.html

https://www.prnewswire.com/news-releases/increase-in-focus-on-use-of-advanced-technology-for-drug-development-research-activities-to-drive-global-biosimulation-market-finds-tmr-301348168.html

https://www.prnewswire.com/news-releases/rise-in-use-of-technologically-advanced-products-in-orthopedic-disease-treatment-creates-lucrative-avenues-for-orthopedic-devices-market-opines-tmr-301355874.html

About Us

“Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”

US Office Contact

90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com/

[kritikarehani]

Nonalcoholic Steatohepatitis (NASH) 2030 | Nonalcoholic Steatohepatitis Market Outlook 2030 | DelveInsight

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.

NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.

DelveInsight's "Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Nonalcoholic Steatohepatitis (NASH) market report provides current treatment practices, emerging drugs, Nonalcoholic Steatohepatitis (NASH) market share of the individual therapies, current and forecasted Nonalcoholic Steatohepatitis (NASH) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Nonalcoholic Steatohepatitis (NASH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geographies covered are:

The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan

Request for sample pages of our report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

Nonalcoholic Steatohepatitis (NASH) Disease Understanding and Treatment Algorithm

The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4).

According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.  

The DelveInsight Nonalcoholic Steatohepatitis (NASH) market report gives a thorough understanding of the Nonalcoholic Steatohepatitis (NASH) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Nonalcoholic Steatohepatitis (NASH). 

Treatment 

It covers the details of conventional and current medical therapies available in the Nonalcoholic Steatohepatitis (NASH) market for the treatment of the condition. It also provides Nonalcoholic Steatohepatitis (NASH) treatment algorithms and guidelines in the United States, Europe, and Japan. 

Nonalcoholic Steatohepatitis (NASH) Epidemiology  

The Nonalcoholic Steatohepatitis epidemiology division provide insights about historical and current Nonalcoholic Steatohepatitis (NASH) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

• Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030].

• We estimate the highest prevalence of NASH in the United States, accounting close to 50% of the total prevalent cases, followed by Japan.

Download free sample pages of our report.

Nonalcoholic Steatohepatitis (NASH) Drug Chapters

Due to the unmet need for an approved therapy for the treatment of NASH, several companies have shifted their focus toward the development of targeted drugs with a novel mechanism of action.

Key players in the market of NASH are Genfit, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Gilead Sciences, Allergan (Tobira Therapeutics), Galmed Pharmaceuticals, Bristol-Myers Squibb, Cirius Therapeutics, Galectin Therapeutics, Immuron, NGM Biopharmaceuticals, Can-Fite BioPharma, Akcea Therapeutics, Oramed Pharmaceuticals, Ascletis, Terns Pharmaceuticals, Enyo Pharma, and others.

We expect that the launch of emerging therapies will fill the void treatment areas shortly. The targeted therapies will have stronger penetration than the off-label therapies, and the market is expected to reach billions. 

Nonalcoholic Steatohepatitis (NASH) Market Outlook

The market for the treatment of Nonalcoholic Steatohepatitis (NASH) is likely to experience significant annual growth over the 2018–2030 study period, as major-market sales are expected to increase by 2030. OCA is expected to grab maximum market share, owing to its development to target all stages of NASH (F1–F4), and with the increasing demand for therapies to treat the advanced stage of NASH, i.e., cirrhosis.

The treatment of NASH depends on the stage of the disease. Currently, there is no approved therapy for the treatment of NASH, yet doctors prescribe certain off-label drugs (supportive therapies) for its management. Lifestyle modifications are, however, the first line of treatment. Lifestyle modifications include going for weight loss combined with an active exercise program along with a planned diet.

Medications are then prescribed in the later stages when lifestyle modifications do not produce significant results. Insulin-sensitizing agents are prescribed in some instances; however, metformin produced good results but temporarily, due to which it is not recommended much. Pioglitazone is suggested in select cases for patients already who have Type II diabetes.

The Nonalcoholic Steatohepatitis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Nonalcoholic Steatohepatitis (NASH) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Nonalcoholic Steatohepatitis (NASH) market in 7MM is expected to change in the study period 2017-2030.

[jesse-pinkman123]

The report examines the Nonalcoholic Steatohepatitis Treatment market with respect to the industry trends, growth rate, prospects, drivers, restraints, threats, and lucrative opportunities, by means of distinguishing the high-growth segments of the market through the various stakeholders.

[expertofmarketinsights-blog]

Nonalcoholic Steatohepatitis Treatment Market Growth Factors 2018 – 2026

Nonalcoholic steatohepatitis treatment (NASH) is a syndrome which causes liver damage in non-alcoholic patients. It develops most often in patients with at least one factors such as dyslipidemia, obesity, and glucose intolerance. NASH pathogenesis is not clearly understood however is considered to be linked with insulin resistance. It is diagnosed with the help of blood tests, imaging tests, and sometimes liver biopsy. Treatment of the NASH includes elimination of causes and risk factors such as reducing fat level in the body. NASH is also considered to be one of the chief causes of cirrhosis which can lead to complete liver failure.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/2279

Market Dynamics

Obesity, high blood pressure and cholesterol level, type 2 diabetes and metabolic syndrome are the major cause of the NASH onset. Increasing prevalence of these conditions worldwide is expected to drive the global nonalcoholic steatohepatitis treatment market growth during the forecast period. According to the International Diabetes Federation 2017 data, approximately 425 million people were suffering from diabetes in the world and 82 million cases were in the South East Asia region which is expected to reach 151 million by 2045.

However, diagnosis of the NASH can be difficult to catch in an early stage and can take years before patients show any sort of symptoms which is a major factor hampering the nonalcoholic steatohepatitis treatment market.

Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) in which a person have hepatitis and inflammation of the liver, and can cause liver damage. NASH can lead to complications, such as cirrhosis and liver cancer. Patients with NASH have high chance of mortality due to liver-related causes such as liver failure.

Lifestyle modification, including change in diet and exercise, is the basic therapy recommended for nonalcoholic fatty liver disease. However, in some cases lifestyle modification is difficult to achieve and to sustain, and therefore required other treatments including medicine.

Currently available drugs for the treatment of NAFLD were historically been given for other indications. For instance, Orlistat, a gut lipase inhibitor, is indicated for decrease in the dietary fats absorption. According to the National Center for Biotechnology Information (NCBI) 2017 study, Orlistat has been approved for treatment of obesity and is available over the counter in the U.S. for weight loss. Orlistat-mediated weight loss is related with reduction in hepatic steatosis.

The global nonalcoholic steatohepatitis treatment market size was valued at US$ 1,119.9 million in 2017 (based on existing approved therapies anti-diabetics, vitamins, dietary supplements, and others) and is expected to witness a CAGR of 42.7% over the forecast period (2018 – 2026).

Nonalcoholic Steatohepatitis Treatment Market - Regional Insights

On the basis of region, the global nonalcoholic steatohepatitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe nonalcoholic steatohepatitis treatment market is expected to foresee significant growth owing to increasing incidence of obesity and fatty liver.

According to the National Health and Nutrition Examination Survey, the proportion of NAFLD among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the U.S. According to the National Institutes of Health, in 2015 nearly 3 to 12% of adults in the U.S. were suffering from NASH. The major reason for this increase was an increase in metabolic risk factors. According to the Journal of Hepatology, in 2013, approximately one-third of adults exhibit a pattern of NAFLD in Europe.

Nonalcoholic Steatohepatitis Treatment Market - Competitive Landscape

Key players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/2279

Detailed Segmentation:

Global Nonalcoholic Steatohepatitis Treatment Market, By Drug:

Cenicriviroc

Elafibranor

Ocaliva (Obeticholic Acid)

Selonsertib

Global Nonalcoholic Steatohepatitis Treatment Market, By Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1–206–701–6702

Email: sales@coherentmarketinsights.com

[reportsanddata]

Non-Alcoholic Steatohepatitis (NASH) Market  Revenue Analysis, Company Revenue Share, Global Forecast Till 2027

The global Non-alcoholic Steatohepatitis (NASH) Market is expected to reach USD 13.38 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.

Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.

North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2018, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111

Further key findings from the report suggest

Elafibranor     is projected to be one of the fastest growing drugs of the NASH market.     The segment is projected to grow at a CAGR of 55.4% in the forecast     period. The drug which is an oral treatment is GENFIT’s lead pipeline     product. It has been positioned as a first-in-class drug to treat NASH.     The drug is currently being evaluated in the clinical Phase 3 study     RESOLVE-IT.

North     American market is forecasted to grow at a CAGR of 53% in the coming     years. The disease is considered to be one of the leading causes of     cirrhosis in adults in the U.S. High incidence of diabetes and obesity in     the region are considered to be the main reason behind increasing     incidence of NASH. Based on American Liver Foundation's National Medical     Advisory Committee currently around 30 million Americans have been     diagnosed with NASH. Additionally, around 90% of the NASH patients suffer     from either obesity or diabetes.

Key participants include

Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1111

For the purpose of this report, Reports and Data have segmented global NASH market on the basis of disease cause, drug type, end-user and region:

·         Disease Cause Outlook (Revenue, USD Million; 2017-2027)

o    Hypertension

o    Heart Disease

o    High Blood Lipid

o    Type 2 Diabetes

o    Obesity

·         Drug Type Outlook (Revenue, USD Million; 2017-2027)

o    Vitamin E & Pioglitazone

o    Ocaliva

o    Elafibranor

o    Selonsertib

o    Cenicriviroc

o    Others

·         End-user Outlook (Revenue, USD Million; 2017-2027)

o    Hospitals

o    Clinics

o    Homecare settings

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1111

·         Regional Outlook

o    North America

·        U.S.

o    Europe

·        Germany

·        UK

o    Asia Pacific

·        China

·        India

·        South-east Asia

o    Latin America

·        Brazil

o    MEA

Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.  

 Browse More Related Reports :

Actigraphy Sensors and Polysomnography Devices Market  Analysis

Non-Invasive Brain Trauma Monitoring Devices Market  Share

[ericvick]

The Flurry of Biotech IPOs Continues. 7 Stocks That Hit the Market.

Text size

Lucira Health is one of seven biotech or health-care-related companies opening for trading Friday.

Courtesy of Lucira

Biotechnology companies continue their race to the public equity markets. Seven companies, all in the biotech or health-care space, made their trading debuts Friday. First out of the gate was Vor Biopharma, whose shares rocketed more than 100%, while Immunocore’s stock also surged.

Of the seven companies trading Friday, six had increased the size of their deals. They include Vor, Bolt, Immunocore Holdings, Lucira Health, Terns Pharmaceuticals, and Pharvaris. Only Angion Biomedica didn’t boost its offering, although the company did price at the top of its expected price range. None of the companies that opened Friday are profitable, and all are trading on the Nasdaq. 

The flock of biotechs making their debuts follows a trio of biotechs—Sana Biotechnology (SANA), Landos Biopharma (LABP), and Sensei Biotherapeutics (SNSE)—that traded Thursday to differing results. Sana stock rose 40% in its first day, while shares of Sensei and Landos both dropped below their offer prices.

“Over the last year, the average return on 115 health-care companies (mostly biotech) that went public was plus-88%. That is why we are seeing so many more of them,” said Kathleen Smith, a principal of Renaissance Capital, in an emailed response to questions.

Newsletter Sign-up

Review & Preview

Every weekday evening we highlight the consequential market news of the day and explain what’s likely to matter tomorrow.

Vor Biopharma (ticker: VOR) was one of the first of Friday’s group to begin trading. The cell-therapy company is developing treatments for patients suffering with hematological malignancies.

Shares jumped 108.3% to close Friday at $37.50.

The Cambridge, Massachusetts company collected nearly $177 million after selling about 9.8 million shares at $18 each—up from 8.8 million shares that Vor planned to sell at $16 to $18 each.

Meanwhile, shares of Bolt (BOLT) surged nearly 61% to end at $32.15. The company, based in Redwood City, California, is developing tumor-targeted therapies to treat cancer.

Late Wednesday, Bolt raised $230 million, selling 11.5 million shares at $20 each. It had increased its offering earlier this week to 10.5 million shares in a range of $18 to $19, after initially filing to sell 8.825 million at $16 to $18.

Immunocore Holdings (IMCR)—which is developing T-cell therapies to treat a broad range of diseases, including cancer and infectious and autoimmune diseases—saw its stock rise 66.2% to close at $43.20.

The U.K. company raised $258.3 million after selling about 9.9 million American depositary shares at $26 each—up from the 8.3 million shares at $23 to $25 that it had planned to offer.

Shares of Lucira Health (LHDX), the only company trading Friday that isn’t a biotech, rose nearly 47% to close at $24.98.  

The medical technology company collected $153 million after selling 9 million at $17 each, up from the 7.8 million shares at $15 to $17 it had planned to offer.

Lucira develops consumer-friendly, single-use test kits for respiratory diseases, like Covid-19 and other illnesses. It has produced the Lucira COVID-19 All-In-One Test Kit, which is powered by two AA batteries, fits in the palm of a hand and provides results in 30 minutes, a prospectus said. 

Terns (TERN) opened Friday at $16.95, a nickel below its offer price, but rebounded. It closed at $18.39, up 8.2%. The Foster City, California company raised $127.5 million after selling 7.5 million shares at $17 each. It had planned to sell 6.25 million at $15 to $17.

Terns is developing small-molecule, single-agent, and combination therapies to treat nonalcoholic steatohepatitis, or NASH, and other chronic liver diseases.

Pharvaris N.V. (PHVS) rose 45% to close its first day of trading at $29. 

Pharvaris collected $165.4 million after selling 8.27 million shares at $20. The company had planned to offer 6.95 million shares at $17 to $19. The Netherlands-based company is developing therapies for rare diseases.

Lastly, shares of Angion Biomedica (ANGN) gained 6.4% to close at $17.02.

The Uniondale, New York company raised $80 million after selling 5 million shares at $16, the top of its $14 to $16 price range. 

Angion is developing small-molecule therapeutics to treat acute organ injuries and fibrotic diseases. Its lead product candidate, ANG-3777, is used to treat acute kidney injury and injuries to other major organs, a prospectus said.

Write to Luisa Beltran at luisa.beltran@dowjones.com

[marketreportsupdates]

Nonalcoholic Steatohepatitis Market Size, Growth rate, Industry Challenges and Opportunities to 2027

The Global Nonalcoholic Steatohepatitis market research report provides an insightful analysis of the current market, along with a futuristic perspective on the growth of the market. The aim of this report is to provide beneficial information to clients, market players, and stakeholders and assist them in making fruitful business decisions according to the information provided. The report offers valuable insights into the market size, market share, revenue, sales volume, and CAGR. The information offered by the report gives an idea about the scope, potential, and profitability of the market.

The recent COVID-19 pandemic has drastically changed the dynamics of the market and resulted in an economic slowdown. The report covers an impact analysis of the pandemic on the overall market. It also includes the changes in demands and factors that might influence the growth or restrain the growth in a post-COVID-19 scenario. The report also consists of the present and future impact of COVID-19 on the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1111

Key participants include Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

The forecast estimation states the global Nonalcoholic Steatohepatitis market is expected to dominate the economic sphere of the world with significant growth in the coming years. The growth is boosted by a change in demand patterns, rapidly developing infrastructure, technological advancements, and product advancements. The current and emerging trends are expected to shape up the industry and help in gaining a strong foothold in the global market to contribute to the revenue generation.

The Global Nonalcoholic Steatohepatitis market is further analyzed on the basis of key companies operating in the business sphere and major geographical regions where the market has a substantial size and growth rate.

Disease Cause Outlook (Revenue, USD Million; 2018-2026)                                        

 Hypertension

 Heart Disease

 High Blood Lipid

 Type 2 Diabetes

 Obesity

Drug Type Outlook (Revenue, USD Million; 2018-2026)

 Vitamin E & Pioglitazone

 Ocaliva

 Elafibranor

 Selonsertib

 Cenicriviroc

 Others

To read more about the report @ https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market

End-user Outlook (Revenue, USD Million; 2018-2026)

 Hospitals

 Clinics

 Homecare settings

Zonal Partition of the Market: North America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

The report covers extensive analysis of market segments that are anticipated to lead by the end of the forecast period (2020-2027). The report puts a special emphasis on the upstream raw materials, downstream buyers, industrial chain analysis, technological and product advancements, and production and manufacturing capacities of the Nonalcoholic Steatohepatitis market. Moreover, the report provides an in-depth analysis of the core segments of the market by analysis of the applications, types, consumption patterns, market drivers and restraints, and challenges to be faced in the market.

The research study focuses on the emerging development patterns and manufacturing processes anticipated to boost the growth of the market. It also includes extensive profiles of prominent contenders of the industry and provides a complete analysis inclusive of their market share, market size, production capacity, sales and distribution network, import/export activity, and product portfolios.

Major objectives of the Global Nonalcoholic Steatohepatitis Report:

·         Analysis and forecast estimation of the Global Nonalcoholic Steatohepatitis Market based on the market segmentation into types, applications, and regions

·         Analysis of micro and macroeconomic factors affecting the global Nonalcoholic Steatohepatitis market

·         Valuable insight into the major drivers, limitations, opportunities, and challenges faced by the global Nonalcoholic Steatohepatitis market and its players

·         In-depth analysis of the prominent contenders along with their business strategies and expansion plans

·         Strategic recommendations to the established companies as well as new entrants to assist in the formulation of investment plans

·         Comprehensive analysis of the competitive landscape of the Nonalcoholic Steatohepatitis industry

To summarize, the report provides a better understanding to the reader about the Nonalcoholic Steatohepatitis industry by offering a detailed explanation of the competitive landscape, industry environment, market projections, growth driving and restraining factors, limitations, entry barriers, and opportunities. The report also covers the regulatory framework, investment opportunities, and other growth driving factors. The report allows the reader to gather insightful information about each segment of the market and provides a historical, present, and prospective outlook of the market.

Thank you for reading our report. To know more about the report or for any queries regarding customization, please connect with us. Our team will provide excellent assistance and make sure the report is tailored to meet your requirements.

Browse Related Reports:-

Purified Human Proteins Market Analysis, Top Players, Demand, Industry Challenges and Opportunities to 2027

Genome Editing Market Size, Demand, Shares, growth and Forecasts to 2027

Contact Us

John W

Head of Business Development

40 Wall St. 28th floor New York City

NY 10005 United States

Direct Line: +1-212-710-1370